ES2527994T3 - Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa - Google Patents

Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa Download PDF

Info

Publication number
ES2527994T3
ES2527994T3 ES12195158.6T ES12195158T ES2527994T3 ES 2527994 T3 ES2527994 T3 ES 2527994T3 ES 12195158 T ES12195158 T ES 12195158T ES 2527994 T3 ES2527994 T3 ES 2527994T3
Authority
ES
Spain
Prior art keywords
aeruginosa
therapeutic agents
bacteriophages
agents containing
containing bacteriophages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12195158.6T
Other languages
English (en)
Inventor
James Soothill
Catherine Hawkins
David Harper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocontrol Ltd
Original Assignee
Biocontrol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0317240A external-priority patent/GB0317240D0/en
Priority claimed from GB0410855A external-priority patent/GB0410855D0/en
Application filed by Biocontrol Ltd filed Critical Biocontrol Ltd
Application granted granted Critical
Publication of ES2527994T3 publication Critical patent/ES2527994T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Una preparación de bacteriófago que comprende uno o más bacteriófagos para su uso en un método terapéutico o profiláctico de tratamiento de una infección bacteriana, en el que: (i) la infección bacteriana comprende o consiste en Pseudomonas aeruginosa (P. aeruginosa) y está caracterizada por la formación de una biopelícula; (ii) dicho uno o más bacteriófagos se dirigen a la P. aeruginosa de dicha infección; y (iii) en dicho método, este debe comprender (a) la administración de dicho uno o más bacteriófagos; (b) permitir que se establezca la replicación de dicho uno o más bacteriófagos; y después (c) la administración de uno o más antibióticos una vez que la replicación de dicho bacteriófago se ha establecido.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21

Claims (1)

  1. imagen1
    imagen2
ES12195158.6T 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa Expired - Lifetime ES2527994T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0317240 2003-07-23
GB0317240A GB0317240D0 (en) 2003-07-23 2003-07-23 Therapeutic agents
GB0410855A GB0410855D0 (en) 2004-05-14 2004-05-14 Therapeutic agents
GB0410855 2004-05-14

Publications (1)

Publication Number Publication Date
ES2527994T3 true ES2527994T3 (es) 2015-02-03

Family

ID=34105984

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12195158.6T Expired - Lifetime ES2527994T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
ES04743566.4T Expired - Lifetime ES2556243T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04743566.4T Expired - Lifetime ES2556243T3 (es) 2003-07-23 2004-07-23 Agentes terapéuticos que contienen bacteriófagos

Country Status (7)

Country Link
US (5) US7807149B2 (es)
EP (2) EP2570130B1 (es)
JP (2) JP5731727B2 (es)
AU (1) AU2004258731B2 (es)
CA (1) CA2533352C (es)
ES (2) ES2527994T3 (es)
WO (1) WO2005009451A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527994T3 (es) 2003-07-23 2015-02-03 Biocontrol Limited Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
WO2006092629A1 (en) * 2005-03-04 2006-09-08 Blaze Venture Technologies Limited Method and device for bacterial sampling
CN100363489C (zh) * 2005-06-16 2008-01-23 华中科技大学同济医学院附属同济医院 一株耐亚胺培南绿脓杆菌噬菌体及其用于治疗耐亚胺培南绿脓杆菌感染的用途
EP1907534B2 (en) 2005-07-12 2024-04-10 Micreos B.V. Bacteriophage and their uses
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
US8956628B2 (en) * 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
US9320795B2 (en) * 2007-12-13 2016-04-26 Zoctis Server LLC Bacteriophage preparations and methods of use thereof
KR20100093626A (ko) * 2009-02-17 2010-08-26 서강대학교산학협력단 슈도모나스 애루지노사에 대한 파아지 치료
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
TW201130980A (en) * 2010-03-02 2011-09-16 Univ Ishou A new lytic phage specific to Klebsiella pneumoniae
WO2013048604A2 (en) 2011-06-28 2013-04-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
CA2871986C (en) * 2012-05-04 2020-11-03 Biocontrol Limited Therapeutic bacteriophage compositions
DE102013106455A1 (de) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Verfahren zur Dekontamination von bakteriologischen Verunreinigungen
PL405911A1 (pl) 2013-11-04 2015-05-11 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Białko o aktywności hydrolitycznej wobec polisacharydowych otoczek bakteryjnych, polinukleotyd kodujący to białko, biologicznie czynny wektor, kompozycja zawierająca białko i jego zastosowanie
US11058131B2 (en) 2015-04-16 2021-07-13 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli O157:H7 bacteriophage Φ241
US10517908B2 (en) 2015-08-13 2019-12-31 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
PT3440200T (pt) * 2016-04-08 2021-04-30 Phico Therapeutics Ltd Bacteriófago modificado
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017189518A1 (en) * 2016-04-25 2017-11-02 Yale University Bacteriophage compositions and uses thereof
CN110719784A (zh) 2017-02-13 2020-01-21 阿玛塔制药公司 治疗性噬菌体组合物
CN109837251B (zh) * 2017-11-27 2022-01-28 菲吉乐科(南京)生物科技有限公司 一种噬菌体保护剂及其制备方法和应用
CA3087338A1 (en) 2018-01-02 2019-07-11 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating staphylococcus infection
WO2019136108A1 (en) 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections
CN108300723B (zh) * 2018-01-17 2022-04-08 天津科技大学 应用于筛选生物被膜抑制剂的报告基因系统
EP3749342B1 (en) 2018-02-07 2024-07-10 Armata Pharmaceuticals, Inc. Bacteriophage for treatment and prevention of bacteria-associated cancers
WO2019231848A1 (en) 2018-05-30 2019-12-05 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
AU2019355036A1 (en) 2018-10-04 2021-05-06 The Westmead Institute for Medical Research Bacteriophage treatment and reduction in inflammatory response
CN112312429B (zh) * 2019-08-02 2022-05-10 华为技术有限公司 一种提升终端设备测量能力的方法、芯片以及终端设备
CA3187281A1 (en) * 2020-06-15 2021-12-23 Laboratory Corporation Of America Holdings Methods for the diagnosis and treatment of biofilm-related infections
US12016892B2 (en) * 2021-04-09 2024-06-25 University of Pittsburgh the Commonwealth System of Higher Education Bacteriophages for treatment of tuberculosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) * 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US4828999A (en) 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
SU1472500A1 (ru) 1987-07-28 1989-04-15 Тбилисский Научно-Исследовательский Институт Вакцин И Сывороток Штамм бактериофага РSеUDомоNаS aeRUGINoSa, используемый дл идентификации и индикации микробов РSеUDомоNаS aeRUGINoSa
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) * 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
AU4381493A (en) * 1992-05-22 1993-12-30 Children's Hospital Of Philadelphia, The Gastrointestinal defensins, CDNA sequences and method for the production and use thereof
US5582825A (en) * 1993-02-24 1996-12-10 Gunze Limited Therapeutic medicine for cystic fibrosis
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
EP0895534A1 (en) 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998047521A1 (en) 1997-04-24 1998-10-29 Idaho Research Foundation, Inc. Phages, methods for growing and detecting them and their use
US20020037260A1 (en) * 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
DE69838473T2 (de) * 1997-12-25 2008-01-17 Nihon Kohden Corp. Gerät zur Übertragung von biologischen Signalen
WO1999037799A1 (en) 1998-01-21 1999-07-29 The Secretary Of State For Defence Antibiotic sensitivity testing
US20040208853A1 (en) * 2000-01-11 2004-10-21 Intralytix, Inc. Method and device for sanitation using bacteriophages
CA2430501A1 (en) 2000-01-11 2001-07-19 Intralytix, Inc. Method for produce sanitation using bacteriophages
US20020001590A1 (en) 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
US6485902B2 (en) 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
ES2252263T3 (es) * 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.
US6461608B1 (en) 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination
RU2186574C1 (ru) 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Препарат поливалентного бактериофага против синегнойной палочки, штаммы бактериофага bacteriophagum pseudomonas aeruginosa спбгма им. и.и. мечникова №05, №03, №06 и №07, используемые при приготовлении поливалентного препарата против синегнойной палочки
ATE355069T1 (de) * 2001-07-18 2006-03-15 Inst Immunologii I Terapii Dos Verfahren zur herstellung polyvalenter bakteriophagenpräparationen zur behandlung bakterieller infektionen
GB0300597D0 (en) 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US6804620B1 (en) 2003-03-21 2004-10-12 Advantest Corporation Calibration method for system performance validation of automatic test equipment
ES2527994T3 (es) 2003-07-23 2015-02-03 Biocontrol Limited Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
US20050051420A1 (en) * 2003-09-05 2005-03-10 Sharper Image Corporation Electro-kinetic air transporter and conditioner devices with insulated driver electrodes
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments

Also Published As

Publication number Publication date
WO2005009451A9 (en) 2006-05-18
JP2006528166A (ja) 2006-12-14
US8388946B2 (en) 2013-03-05
EP2570130B1 (en) 2014-11-26
JP5731727B2 (ja) 2015-06-10
US7807149B2 (en) 2010-10-05
EP2570130A1 (en) 2013-03-20
CA2533352A1 (en) 2005-02-03
ES2556243T3 (es) 2016-01-14
EP1663265A1 (en) 2006-06-07
AU2004258731B2 (en) 2010-02-25
JP5856556B2 (ja) 2016-02-10
US20120114611A1 (en) 2012-05-10
JP2013049700A (ja) 2013-03-14
CA2533352C (en) 2016-01-19
EP1663265B1 (en) 2015-09-23
US20110020290A1 (en) 2011-01-27
US9687514B2 (en) 2017-06-27
US8105579B2 (en) 2012-01-31
WO2005009451A1 (en) 2005-02-03
US20070190033A1 (en) 2007-08-16
AU2004258731A1 (en) 2005-02-03
US20180055895A1 (en) 2018-03-01
US20130209408A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
ES2527994T3 (es) Agentes terapéuticos que contienen bacteriófagos frente a P. aeruginosa
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
ES2526521T3 (es) Composiciones de antibiótico para el tratamiento del oído
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
UY26380A1 (es) Inhibidores de fab i
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
NO20042271L (no) Formuleringer som inneholder en cefalosporinforbindelse og deres anvendelse for behandling av bakterielle infeksjoner i katter og hunder
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
NO20034094D0 (no) Sammensetninger som omfatter et antidiar±middel og et epotilon eller et epotilonderivat
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
CL2008001303A1 (es) Compuestos derivados de heterociclos, moduladores de gamma secretasa; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento del alzheimer.
CU23260B7 (es) PREPARADO FARMACéUTICO DE MOXIFLOXACINA
EA200601654A1 (ru) Ингибиторы интегразы вич
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
CL2012000586A1 (es) Uso de al menos 20 mg de un aerosol de una solucion que comprende levofloxacina u ofloxacina y un cation bivalente o trivalente, para el tratamiento de una infeccion pulmonar en un paciente con fibrosis quistica.
DE60331849D1 (de) Antibakterielle wirkstoffe
AR045572A1 (es) Una combinacion que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil-3-sulfonamida y un analogo lhrh y/o un bifosfonato
NO20051539L (no) N-biarylmetylaminosykloalkankarboksamidderivater
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
NO20031648L (no) Farmasöytiske lösninger av modafinilforbindelser
AR028041A1 (es) El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoaria en mamiferos
NO990440L (no) Preparat som innbefatter mupirocin og klorheksidin
AU2002354900A1 (en) Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections